PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 2, 20250 citationsOpen Access

Nanopore-based cell-free DNA fragmentation and methylation profiles from the cerebral spinal fluid of patients with lung cancer brain metastases

View Full Paper
TCTianqi ChenXBXiangqi BaiGBGeorgiana Burnside

Key Points

  • Nanopore sequencing identified unique fragmentation patterns in cfDNA from cerebrospinal fluid compared to plasma-derived cfDNA.
  • Cancer patients exhibited significantly lower hydroxymethylation levels in cfDNA, suggesting distinct molecular features.
  • Comparison with healthy controls highlighted significant differences in methylation and fragmentation profiles in cancer patients.
  • Findings may assist in the development of non-invasive biomarkers for assessing prognosis in NSCLC patients with brain metastases.

Abstract

Non-small cell lung cancer ( NSCLC ) patients with brain metastases ( BMET ) have a poor prognosis. Cerebrospinal fluid ( CSF ) is a source of cell free DNA ( cfDNA ) from the brain and its methylation and fragmentation properties may be an indicator of NSCLC-BMET. We applied a nanopore single-molecule sequencing approach to characterize the fragmentation, methylation and hydroxymethylation patterns present in CSF-derived cfDNA from NSCLC-BMET patients (N=15). We compared the cancer cfDNA finding to non-cancer healthy controls (N=11) and their CSF cfDNA. We also compared the fragmentation patterns between CSF-derived cfDNA and plasma-derived cfDNA. We observed enriched mono-nucleosome levels and significantly higher mono-/trinucleosome ratios in cancer patients. Comparison with plasma-derived cfDNA further confirmed the unique fragmentation features of CSF-derived cfDNA. Distinct methylation and hydroxymethylation patterns were observed between cancer and control CSF samples. We observed significantly lower degree of hydroxymethylation in cancer patients compared to healthy controls and the affected genes had different pathway profiles. CSF cfDNA in patients with NSCLC-BMET had a distinct profiles of DNA fragmentation, methylation and hydroxymethylation.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d035ehttps://doi.org/10.1101/2025.07.28.667300
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases2024 · 16 citations
  2. 2Gene Set Knowledge Discovery with Enrichr2021 · 3,865 citations
  3. 3Presence of Brain Metastases at Initial Diagnosis of Cancer: Patient Characteristics and Outcome2019 · 16 citations
  4. 4Low level of 5-Hydroxymethylcytosine predicts poor prognosis in non-small cell lung cancer2016 · 33 citations
  5. 5Tumor Suppressor 4.1N/EPB41L1 is Epigenetic Silenced by Promoter Methylation and MiR-454-3p in NSCLC2022 · 9 citations